Over the past decade, Germany’s share of global clinical trial activities has dropped year on year. The country accounted for just 3.9% of trials in 2021, down from 7.2% in 2012. Late last year, the German Government published its National Pharma Strategy, which is designed to reverse this trend. Aiming to revitalize the country’s pharmaceutical … Read more
At the beginning of September, Velocity Clinical Research topped Business North Carolina’s 2024 Fast 40 list. It was our third time receiving the award, which recognizes the fastest-growing mid-market businesses in the state. For a clinical trials organization to achieve this level of scale is notable. The clinical trials sector in the US is typically … Read more
In his latest article for the Association of Clinical Research Professionals (ACRP), Paul Evans outlines how integrated site organizations can pave the way for AI adoption and generate tangible value for the industry. For sites, investigators, and patients, Gen AI has the potential to streamline recruitment, reduce manual labor, and accelerate trial processes. By leveraging … Read more
The pandemic left many notable developments in its wake, not least the increased focus on improving diversity in clinical trials. This issue was thrust into the spotlight during Operation Warp Speed — the accelerated development of a COVID-19 vaccine in the U.S. — and is one Jerome Adams, MD, MPH, who served as U.S. General … Read more
In this new article for VentureBeat, Raghu Punnamraju, Chief Technology Officer at Velocity, discusses why data science alone is not enough to ensure product success. In this insightful piece, Raghu explores the importance of blending technical excellence with commercial understanding, highlighting the need for lean-value principles, the role of AI, and the power of data … Read more
Paul Evans was recently featured in a Business North Carolina article discussing the emerging impact of artificial intelligence on North Carolina’s clinical research industry. As Paul notes, “Our industry is in the same place as most people with AI. We’ve seen a step change. Everybody started with efficiency gains, back-office functions. Then you move on … Read more
It’s been just over a year since the monoclonal antibody Lecanemab received traditional approval from the FDA as a treatment for Alzheimer’s disease. This marked a turning point in the disease’s treatment, a drug that interrupted progression for the first time rather than simply addressing the symptoms. It was this type of breakthrough that Robert … Read more
Raghu Punnamraju, Chief Technology Officer at Velocity, was recently interviewed by CIO News about applying a lean-value approach to our technical product management, engineering, and architectural strategies. Through the development of our VISION platform, and new frameworks that leverage LLMs, this article details how Raghu and our team in Hyderabad, India, are continuously delivering solutions … Read more
The Velocity team had the honor of hosting former U.S. Surgeon General and Chairman of the Board of TOTAL Diversity Clinical Trial Management, Jerome Adams, MD, MPH. He joined an internal call to discuss the importance of diversity in clinical research, highlighting the need for diverse patient populations in clinical trials to ensure new treatments … Read more
The narrative that’s been peddled for the past three decades has seen obesity become mired in controversy, leading many – even healthcare professionals – to view it as a lifestyle choice rather than a disease. Nearly 40% of the global population has a body mass index (BMI) higher than 25 kg/m2, meaning they’re overweight or … Read more